BICO Group AB Class B (SE:BICO)
:BICO
BICO Stock Chart & Stats
kr18.16
-kr2.08(-4.75%)
At close: 4:00 PM EST
kr18.16
-kr2.08(-4.75%)
Day’s Range― - ―
52-Week Rangekr15.30 - kr42.46
Previous CloseN/A
Volume245.45K
Average Volume (3M)288.59K
Market Cap
kr1.19B
Enterprise Valuekr1.38B
Total Cash (Recent Filing)kr1.28B
Total Debt (Recent Filing)kr1.50B
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Apr 29, 2026EPS Estimate
-1.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding69,074,900
10 Day Avg. Volume264,488
30 Day Avg. Volume288,586
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.85
Price to Sales (P/S)0.99
P/FCF Ratio26.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.19
Revenue Forecast (FY)kr1.60B
Bulls Say, Bears Say
Bulls Say
Improving Cash Generation And Pro‑forma LiquidityA materially stronger liquidity position and a deliberate capital raise create a multi‑quarter runway to fund prioritized R&D, small acquisitions and commercialization. Positive free cash flow in 2024–2025 plus ~SEK 670m pro forma cash improves financial optionality and reduces near‑term refinancing risk.
Q4 Profitability Recovery And Margin ImprovementA clear Q4 margin recovery demonstrates the business can achieve sustainable unit economics after cost actions. If management maintains the Q4 OpEx base and execution, improved incremental margins can convert revenue growth into durable cash generation and reduce reliance on external funding.
Strategic Pivot To Lab Automation, Software And AIShifting focus to software, AI and lab automation increases recurring revenue potential, customer stickiness and higher gross margin mix. Partnerships and product launches signal structural repositioning (BICO 2.0) that, if sustained, supports more predictable revenues and scalable margins over multiple quarters.
Bears Say
Multi‑year Revenue ContractionThree consecutive years of declining revenue indicate persistent demand or portfolio struggles; reversing this trend requires sustained commercial recovery across segments. Continued top‑line shrinkage limits operating leverage, hinders margin recovery and constrains the ability to scale R&D or absorb fixed costs.
Very Low Full‑year Profitability And Earnings VolatilityNear‑breakeven full‑year EBITDA with large quarterly swings signals weak earnings quality and exposed fixed‑cost base. Volatile profitability reduces internal funding for growth, increases reliance on external financing, and raises execution risk while management stabilizes operations and capitalisation policies.
Worsening Leverage And Limited Cash Coverage Of DebtAlthough equity remains meaningful, rising leverage and operating cash flow that covers a tiny share of debt reduce financial flexibility. This magnifies the impact of further earnings setbacks, increases refinancing risk over the medium term, and could limit the pace of strategic M&A or R&D investment.
BICO Group AB Class B News
BICO FAQ
What was BICO Group AB Class B’s price range in the past 12 months?
BICO Group AB Class B lowest stock price was kr15.30 and its highest was kr42.46 in the past 12 months.
What is BICO Group AB Class B’s market cap?
BICO Group AB Class B’s market cap is kr1.19B.
When is BICO Group AB Class B’s upcoming earnings report date?
BICO Group AB Class B’s upcoming earnings report date is Apr 29, 2026 which is in 30 days.
How were BICO Group AB Class B’s earnings last quarter?
BICO Group AB Class B released its earnings results on Feb 18, 2026. The company reported -kr0.82 earnings per share for the quarter, missing the consensus estimate of -kr0.467 by -kr0.353.
Is BICO Group AB Class B overvalued?
According to Wall Street analysts BICO Group AB Class B’s price is currently Overvalued.
Does BICO Group AB Class B pay dividends?
BICO Group AB Class B does not currently pay dividends.
What is BICO Group AB Class B’s EPS estimate?
BICO Group AB Class B’s EPS estimate is -1.15.
How many shares outstanding does BICO Group AB Class B have?
BICO Group AB Class B has 69,074,900 shares outstanding.
What happened to BICO Group AB Class B’s price movement after its last earnings report?
BICO Group AB Class B reported an EPS of -kr0.82 in its last earnings report, missing expectations of -kr0.467. Following the earnings report the stock price went up 12.875%.
Which hedge fund is a major shareholder of BICO Group AB Class B?
Currently, no hedge funds are holding shares in SE:BICO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BICO Group AB Class B
BICO Group AB Class B (BICO) is a leading company in the biotechnology sector, focusing on innovative solutions in the life sciences and healthcare industries. The company specializes in biofabrication, offering advanced technologies and services for the development of tissue engineering and regenerative medicine. BICO's core products include bioprinters, biomaterials, and related software, which enable researchers and medical professionals to create and manipulate biological structures for research and therapeutic applications.
BICO Company Deck
BICO Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: the company executed its strategic repositioning (BICO 2.0), strengthened its cash position through a EUR 40m bond issuance, reduced debt and demonstrated a clear Q4 recovery with strong margins and Biosero momentum. However, full-year financials were weak (organic sales -8%, adjusted EBITDA only SEK 5m, Lab Automation full-year decline -26% and negative EBITDA), and the business faced notable macro headwinds (US academia funding cuts, FX pressure and cautious CapEx). Product launches, partnerships and AI-enabled offerings provide a foundation for growth, but near-term performance still reflects industry and legacy operational challenges.View all SE:BICO earnings summariesTechnical Analysis
CellaVision AB
―
Senzime AB
―
Bactiguard Holding AB
―
C-Rad AB Class B
―
Sedana Medical AB
―
Options Prices
Currently, No data available
---